The Case of Purdue Pharma, the Sackler Family, and the Opioid Crisis
In the first of two short posts today, we will look at the
case of the billionaire Sackler Family and their remarkable effect upon
American society. The family, who own Purdue
Pharma amongst a list of other ventures, have this week seen a massive
legal action taken against them by the State of New York who argue that the
company is ‘responsible
for the opioid epidemic’ sweeping through the United States.
The attorney-general for New York has called the lawsuit the
‘nation’s
most extensive’ with respect to the pharmaceutical industry and comes right
on the heels of a $270
million suit that was settled in the State of Oklahoma on exactly the same
grounds. Whilst the company and the billionaire family who own it did not admit
guilt (settling parties rarely do, hence why they settle outside of court) it
has potentially opened the trapdoors for litigation. It comes as no surprise then
that the company is reportedly
considering bankruptcy proceedings in the face of such an onslaught.
The company, which began life as the Purdue Frederick
Company in Manhattan in 1892, was bought by the Sackler
family in 1952 by
Dr Raymond and Dr Mortimer Sackler. In the 1980s the company began
manufacturing products that were derivatives of opioids, like morphine. In 1996, this
programme is extended and the company develops ‘OxyContin’, or ‘oxycodene’ in
an ‘extended release’ format. In 2005 the company begins developing
increased security around OxyContin which is demonstrative of their
understanding of the market for these drugs, and in 2010 OxyContin is
redeveloped to include extra warnings over its usage. Nevertheless, the sale of
what has been called ‘heroin
in a pill’, has become a societal ill unlike many others (at least one that
is officially sold to the public). The National Institute of Drug Abuse states
that more than 130
people die every day after overdosing on opioids, whilst the Department of
Health and Human Services declared a public
health emergency in 2017 and themselves estimate that more than 11 million
people misused prescription opioids in 2017 alone.
The scale of the disaster is tremendous and the opening of
extensive lawsuits will likely see the end of Purdue Pharma and its
competition. However, that is probably wishful thinking. The reality is that
the people behind the company will not suffer or be penalised, the systems they
developed where salespeople were paid
six-figure bonuses for misleading Doctors will not be regulated, and
moreover there is scope for the companies to make even more money. Rather
remarkably, it has been revealed that not only do Purdue have massive stakes in
other more
generalised opioid products, they are now busy
marketing and aggressively pushing the cure
to the social problem they themselves
exacerbated! It is all rather remarkable but not in the least bit
surprising – that big business is encouraged to act in this manner at the cost
of the public is a systemic norm that
has been accepted. One would like to think the New York lawsuit would cause
damage to the operations of the firm and the family, but considering the fact
the cure is raking in billions of
dollars, it is very unlikely.
Keywords – Pharmaceuticals, US, Opioid crisis, business,
law, @finregmatters
Comments
Post a Comment